Browse the graph
Therapeutic areas
Every pre-ticker company on the graph is classified into one therapeutic area from its grants, trials, and filings. Pick an area to see how the pipeline is distributed across stages and which companies are moving. The counts below are public federal records; the full dossiers follow your seat.
- Oncology19,472 companies
Solid tumors, hematologic cancers, and the platforms aimed at them — the deepest area on the graph, and the one the free tier follows.
Open Oncology → - Neuro7,975 companies
Neurodegeneration, psychiatry, pain, and CNS platforms, from the grant that funded the target to the first trial.
Open Neuro → - Immunology8,162 companies
Autoimmune, inflammation, and immune-modulating programs across the spin-out-to-raise crosswalk.
Open Immunology → - Rare disease748 companies
Rare and orphan-disease programs, where a single trial can define a company and non-dilutive grant funding runs deep.
Open Rare disease → - Other0 companies
Diagnostics, tools, and programs the classifier has not placed in one of the disease areas above.
Open Other →
Company counts are drawn from public federal filings and shown identically to every visitor. Classification is derived from a company’s grants, trials, and filings, and can be revised as new records arrive. Methodology · Coverage